Novel strategies for managing dyslipidemia: treatment beyond statins (Q38074335)

28 August 2017

1 reference

title

Novel strategies for managing dyslipidemia: treatment beyond statins (English)

1 reference

28 August 2017

1 reference

Hua Ling

1

1 reference

28 August 2017

Tammy L Burns

series ordinal

2

1 reference

28 August 2017

Daniel E Hilleman

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

28 August 2017

Postgraduate Medicine

1 reference

28 August 2017

124

1 reference

28 August 2017

43-54

1 reference

28 August 2017

6

1 reference

The epidemiologic transition theory

28 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Non-adherence to statin therapy: a major challenge for preventive cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Anacetrapib: hope for CETP inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Molecular basis of PCSK9 function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

PPAR dual agonists: are they opening Pandora's Box?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Antisense oligonucleotides for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Abetalipoproteinemia: two case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.11.2612

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.11.2612

1 reference

28 August 2017

1 reference